Participated · Series A · Nov 2022

Torigen Pharmaceutical is a commercial-stage animal health biologics company that aims to innovate pet cancer treatment by leveraging the pet’s immune system to create personalized cancer immunotherapies. Led by CEO Ashley Kalinauskas, the company is a spin-out from the University of Notre Dame and is based in Farmington, CT. Torigen is focused on developing new biologic products to treat cancer in companion animals. The company says it will use the proceeds from its latest financing to continue to develop new products and expand its salesforce. The company is described as commercial-stage. The recent financing provides additional capital to support its product development and commercial expansion.

Participated · Series C · Jan 2020

P2 Science develops proprietary, nature-inspired chemical processes to produce renewable specialty ingredients with a focus on performance and sustainability at scale. The company has launched beauty ingredients including Citrolatum® P, a 1:1 plant-based petrolatum replacement, and CitroComplex® Nourish, a natural oil blend for skin and hair, and entered a strategic partnership with Algenesis to develop 100% biobased, biodegradable polyurethanes. P2 has been recognized by Fast Company in 2025 and 2026 and was selected for L'Oréal's L'AcceleratOR sustainable innovation accelerator. It recently received $2.8 million in non-dilutive ARPA-E funding to accelerate catalyst innovation via AI-enhanced autonomous labs. The company plans to use its new equity financing to scale commercial production in beauty and expand its platform into adjacent markets such as aroma technologies, performance polymers, home care, coatings, and crop care. P2 was co-founded by Professor Paul Anastas and Dr. Patrick Foley at Yale's Center for Green Chemistry and Green Engineering and is based in Woodbridge, Connecticut.

Participated · Series D · Jun 2019

Payveris offers the MoveMoney Platform, an open-API cloud-based platform that enables financial institutions to control, simplify, and extend digital money movement across applications and devices. At the time of the announcement it served over 180 credit union clients. Payveris announced the formation of PayverisCU, a newly formed Credit Union Service Organization, and VyStar Credit Union served as the initial investor in a $10 million capitalization to establish the CUSO's operations. The capital will be used to accelerate product development of the MoveMoney Platform and to build digital member experiences focused on money movement, money management, and financial wellness. Payveris said it will continue platform development, expanding open APIs to support debit and credit cards, additional real-time payment rails, content aggregation, artificial intelligence, enhanced fraud management, and back-office user support tools. Payveris positions PayverisCU as a collaborative vehicle with progressive credit unions to deliver next-generation digital payments and reduce user-experience friction. Payveris is a provider of digital money-movement technology to financial institutions, based in Cromwell, Conn. Led by CEO Ron Bergamesca, the company created The MoveMoney Platform, an Open API cloud-based platform that enables financial institutions to control, simplify and extend digital money movement capabilities to any application or device. The platform is designed to reduce operating costs and future-proof IT investments. Payveris intends to use recent funding to accelerate client acquisition, drive platform innovation and scale up the organization. The company recently completed a Series D financing, strengthening its balance sheet for growth. No operating metrics were disclosed in the article. Payveris provides a cloud-based, open API digital payment and money-movement platform designed to help financial institutions compete in a digital world. Its platform supports electronic bill presentment and payment, person-to-person (P2P) transfers, external (A2A) account transfers, and business payments through a single unified platform using APIs and widgets. The company positions its technology to give financial institutions control of the user experience, extend payment capabilities into third-party applications, accelerate payments, and reduce operating costs. Payveris has rapidly expanded its customer base, adding more than 100 financial-institution customers in the past two quarters and now serves 180 banks and credit unions and 21 fintech partners. The team has grown by 40 percent recently, including the addition of Mohan Chunduri as senior vice president of operations. The company says it will use the new funding to continue rapid growth and develop new payment platform features over the coming year. Payveris offers a cloud-based ePayments platform that provides bill payment and interbank transfer solutions to banks, credit unions and distribution partners. The company's platform is delivered via APIs and a library of moveable widgets, enabling white-label, integrated and customized payment experiences for financial institutions. Payveris positions its cloud-based payment-processing platform as a lower-cost alternative to other processing solutions and says it is the only cloud-based payment-processing platform in the market. Its product set targets community banks, credit unions, core processors and online-banking providers and emphasizes improved user experience and regulatory alignment. The company has a fast-growing roster of bank and credit union clients and highlights its ability to help institutions reclaim payment services. Payveris plans to use new funds to support its distribution network, expand sales and marketing, and continue investment in its cloud platform.

Participated · Series C · May 2019

IsoPlexis develops proprietary single-cell functional proteomic technology, including proteomic barcode chips and software-enabled IsoLight and IsoSpark detection systems, to profile secreted proteomes, phosphoproteomes, and metabolomes from single cells. Its end-to-end solutions are used to phenotype immune cells and connect in vivo biology to therapeutic development, with applications in cancer immunotherapy, cell and gene therapy, COVID-19, and autoimmune disease. The company says it has placed more than 100 systems and employs over 200 people, and its products are used by 15 of the top 15 global pharmaceutical companies and by approximately 45% of comprehensive cancer centers. IsoPlexis plans to use the financing to expand global commercial and R&D teams, increase operational capacity to meet demand, and accelerate its next-generation single-cell biology product development roadmap. The company positions its platform to provide new layers of biological data and help predict complex responses to therapies and disease. IsoPlexis is a Branford, Conn.-based developer of single-cell functional proteomics technology. Its core product is the IsoLight single-cell proteomic analysis platform, used globally by biotech, pharma, and academic medical centers to address challenges in cell therapy, cancer immunology, and inflammatory disease. The company says its systems accelerate research into cancer and a range of the world’s toughest diseases. IsoPlexis has expanded its operational, manufacturing, and commercial teams across the US, Europe, and Asia and employs 130 people. It intends to use recent funding to drive global commercial expansion of the IsoLight platform and in 2020 plans to expand applications and release products addressing innate & myeloid function, tumor cell signaling, and other high-need research areas. The company is led by CEO and co-founder Sean Mackay. IsoPlexis develops integrated single-cell detection systems and biomarkers that reveal unique immune signals in small subsets of cells to advance immunotherapies and targeted therapies. Its IsoLight system launched in 2018 and has been deployed at cancer centers and biopharma organizations across the US, Europe and China. Customers have released datasets using the IsoPlexis platform on CAR-T, TCR-T, CRISPR-edited T cells, tumor-infiltrating lymphocytes and checkpoint-immunotherapy patient samples; its single-cell polyfunctional strength product predicted CAR T-cell therapy responses pre-therapy. The company is preparing multiple 2019 product launches including single-cell polyfunctional inflammation solutions for neuroinflammation and autoimmunity, innate and myeloid cell solutions, single-cell energy-state assays, and tumor resistance assays. IsoPlexis leverages an internal application engine and partnerships with university professors and co-founders to build new single-cell products. The company has 105 employees and plans to expand its global operational, manufacturing, and commercial teams across the US, Europe and Asia. IsoPlexis Corporation, a Branford, Conn.-based life science company, raised $13.5M in a Series B financing. The company intends to use the funds for continued product development and marketing to expand use of its IsoCode assay and IsoLight system by trial centers and biopharmaceutical companies focused on oncology and other disease areas. Led by CEO and co-founder Sean Mackay, IsoPlexis uses a next-generation diagnostic and therapeutic platform to identify patient responses at the single-cell level. The IsoCode assay and IsoLight can capture 42 different secreted proteins per cell across thousands of single cells simultaneously, producing a precise functional profile of tumor-reactive T-cells in each patient. That functional profiling enables researchers to better predict and understand complex cancer patient response. The system is also being used to advance research and therapeutic development in infectious diseases, multiple sclerosis, systemic lupus and other high-need areas. IsoPlexis develops a proprietary single-cell multiplexing immunoassay and accompanying software suite that enables detailed biological characterization of important immune and cancer cell subsets within heterogeneous populations. Its platform is intended to help discover novel biomarkers and more accurately test molecules for clinical activity against heterogeneous cell subsets. The company is led by CEO Sean Mackay and is a Yale startup supported by the Yale Entrepreneurial Institute and Office of Cooperative Research; its technology originates from the laboratory of Dr. Rong Fan. IsoPlexis planned engineering and software updates and a beta product finalization as near-term product objectives. The company also aimed to support additional hospital and clinical case studies as part of its development pathway. Funding needs described include product development and working capital to advance commercial readiness.

Participated · Series B · Oct 2013

Precipio Diagnostics LLC, based in New Haven, Conn., provides pathology diagnostic services to community oncologists and hospitals. Led by CEO Ilan Danieli, the company has 14 employees and has exclusively licensed several diagnostic technologies developed at Yale, which it is bringing to market. It commenced sales about a year and a half prior to the article and has produced more than 800 diagnostic reports for patients worldwide. The company raised $1.8M in Series B funding from several investors. Backers included Connecticut Innovations, which invested $750,000 through its Eli Whitney Fund and whose managing director Kevin Crowley joined Precipio’s board. Other participants were Ironwood Capital, Enhanced Capital, Kuzari Capital and individual investors; CI had previously provided a $500k loan in 2012 through the Bioscience Facilities Fund.